WHAT IS CLAIMED IS:

1. A pharmaceutical composition multi-unit dosage form comprising at least two discrete unit dosage forms bound to one another by a coating and/or matrix, each of said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, said unit dosage forms together comprising a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said coating and/or matrix is formulated for immediate release of said unit dosage forms upon oral administration, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, and wherein at least 50 weight percents of the unit dosage forms consists of said absorption enhancer.

2. The multi-unit dosage form of claim 1, being capable of disintegrating in gastric fluid and/or in saliva to thereby release said unit dosage forms.

3. The multi-unit dosage form of any one of claims 1 to 2, comprising from 3 to 10 of said discrete unit dosage forms.

4. The multi-unit dosage form of any one of claims 1 to 3, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

5. The multi-unit dosage form of any one of claims 1 to 3, wherein said therapeutically active agent is a BCS Class III agent.

6. The multi-unit dosage form of any one of claims 1 to 3, wherein said therapeutically active agent is a polypeptide.

7. The multi-unit dosage form of claim 6, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof.

8. The multi-unit dosage form of any one of claims 1 to 7, for use in the treatment of a condition treatable by oral administration of said therapeutically active agent in a subject in need thereof.

9. A pharmaceutical composition unit dosage form comprising a therapeutically active agent and an absorption enhancer, for use in the treatment of a condition treatable by said therapeutically active agent, said treatment comprising concomitant oral administration of at least two of the unit dosage form, wherein said at least two of said unit dosage form together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, and wherein at least 50 weight percents of the unit dosage form consists of said absorption enhancer.

10. The unit dosage form of claim 9, wherein said treatment comprises concomitant oral administration of from 3 to 10 of the unit dosage form.

11. The unit dosage form for use according to any one of claims 9 to 10, wherein said treatment comprises reducing a variability of Cmax and/or AUC of plasma concentrations of said therapeutically active agent.

12. The unit dosage form for use according to any one of claims 9 to 11, wherein said treatment comprises increasing a Cmax and/or a bioavailability of said therapeutically active agent.

13. The unit dosage form for use according to any one of claims 9 to 12, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

14. The unit dosage form for use according to any one of claims 9 to 12, wherein said therapeutically active agent is a BCS Class III agent.

15. The unit dosage form for use according to any one of claims 9 to 12, wherein said therapeutically active agent is a polypeptide.

16. The unit dosage form for use according to claim 15, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof.

17. A pharmaceutical composition unit dosage form comprising less than 200 µg of parathyroid hormone or a fragment thereof, and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof.

18. The unit dosage form of claim 17, for use in the treatment of a condition treatable by said parathyroid hormone or a fragment thereof, said treatment comprising concomitant oral administration of at least two of said unit dosage form, wherein said at least two of said unit dosage form together comprise a therapeutically effective amount of said parathyroid hormone or a fragment thereof and an effective amount of said absorption enhancer.

19. The unit dosage for use according to any one of claims 16 and 18, wherein said condition treatable by said parathyroid hormone or a fragment thereof is

selected from the group consisting of hypoparathyroidism, osteoporosis, and a medical condition associated with a bone fracture and/or bone defect.

20. A kit comprising a plurality of sets of at least two unit dosage forms, said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, wherein said at least two unit dosage forms together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, and wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof.